Paediatric pharmacokinetics: Key considerations

British Journal of Clinical Pharmacology

Volumn 79, Issue 3, 2015, Pages 395-404

  Batchelor, Hannah Katharine ^a   Marriott, John Francis ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

absorption; biopharmaceutics; clinical trial; paediatric; paediatric drug development; pharmacokinetics

Indexed keywords

ABSORPTION; ADULT; ANATOMY; ARTICLE; BLOOD SAMPLING; CHILD; CLINICAL TRIAL (TOPIC); DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; HEALTH CARE; HEALTH CARE PERSONNEL; HUMAN; INFANCY; INTESTINE; NOCICEPTION; PAIN ASSESSMENT; PHARMACODYNAMICS; PHARMACOKINETICS; PHYSIOLOGICAL PROCESS; PHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BINDING; SAMPLE SIZE; STUDY DESIGN; BIOLOGICAL MODEL; BLOOD; DRUG INACTIVATION; INTESTINE ABSORPTION; METABOLISM; PEDIATRICS; TISSUE DISTRIBUTION; URINE;

DRUG;

CHILD; CLINICAL TRIALS AS TOPIC; HUMANS; INACTIVATION, METABOLIC; INTESTINAL ABSORPTION; MODELS, BIOLOGICAL; PEDIATRICS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; TISSUE DISTRIBUTION;

EID: 84929990474     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12267     Document Type: Article

References (99)

1. EMA. ICH Topic E11. Clinical investigation of medicineal products in the paediatric population. CPMP/ICH/2711/99. 2001. Available at http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500002926.pdf (last accessed 11 October 2013).
2. Bowles A, Keane J, Ernest T, Clapham D, Tuleu C,. Specific aspects of gastro-intestinal transit in children for drug delivery design. Int J Pharm 2010; 395: 37-43.
3. Kaye JL,. Review of paediatric gastrointestinal physiology data relevant to oral drug delivery. Int J Clin Pharm 2011; 33: 20-24.
4. Mooij MG, de Koning BA, Huijsman ML, de Wildt SN,. Ontogeny of oral drug absorption processes in children. Expert Opin Drug Metab Toxicol 2012; 8: 1293-1303.
5. Jöhr M,. Unerwünschte Wachheit. Anaesthesist 2006; 55: 1041-1050.
6. Grand RJ, Watkins JB, Torti FM,. Development of the human gastrointestinal tract. A review. Gastroenterology 1976; 70: (5I): 790-810.
7. Pedersen S, Steffensen G,. Absorption characteristics of once-a-day slow-release theophylline preparation in children with asthma. J Pediatr 1987; 110: 953-959.
8. Strolin Benedetti M, Whomsley R, Baltes EL,. Differences in absorption, distribution, metabolism and excretion of xenobiotics between the paediatric and adult populations. Expert Opin Drug Metab Toxicol 2005; 1: 447-471.
9. Bartelink IH, Rademaker CM, Schobben AF, van den Anker JN,. Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations. Clin Pharmacokinet 2006; 45: 1077-1097.
10. Huang NN, High RH,. Comparison of serum levels following the administration of oral and parenteral perparations of penicillin to infants and children of various age groups. J Pediatr 1953; 42: 657-668.
11. Lange D, Pavao JH, Wu J, Klausner M,. Effect of a cola beverage on the bioavailability of itraconazole in the presence of H2 blockers. J Clin Pharmacol 1997; 37: 535-540.
12. Perez de la Cruz Moreno M, Oth M, Deferme S, Lammert F, Tack J, Dressman J, Augustijins P,. Characterization of fasted-state human intestinal fluids collected from duodenum and jejunum. J Pharm Pharmacol 2006; 58: 1079-1089.
13. Navarro J, Schmitz J,. Paediatric Gastroenterology. Oxford: Oxford University Press, 1992.
14. Zughaid H, Forbes B, Martin GP, Patel N,. Bile salt composition is secondary to bile salt concentration in determining hydrocortisone and progesterone solubility in intestinal mimetic fluids. Int J Pharm 2012; 422: 295-301.
15. van Elburg RM, Fetter WP, Bunkers CM, Heymans HS,. Intestinal permeability in relation to birth weight and gestational and postnatal age. Arch Dis Child Fetal Neonatal Ed 2003; 88: F52-55.
16. Zakeri-Milani P, Valizadeh H, Tajerzadeh H, Azarmi Y, Islambolchilar Z, Barzegar S, Barzegar-Jalali M,. Predicting human intestinal permeability using single-pass intestinal perfusion in rat. J Pharm Pharm Sci 2007; 10: 368-379.
17. Corpeleijn WE, van Elburg RM, Kema IP, van Goudoever JB,. Assessment of intestinal permeability in (premature) neonates by sugar absorption tests. Methods Mol Biol 2011; 763: 95-104.
18. Weaver LT, Laker MF, Nelson R,. Intestinal permeability in the newborn. Arch Dis Child 1984; 59: 236-241.
19. Kalach N, Rocchiccioli F, de Boissieu D, Benhamou P-H, Dupont C,. Intestinal permeability in children: variation with age and reliability in the diagnosis of cow's milk allergy. Acta Paediatr 2001; 90: 499-504.
20. Mushak P,. Gastro-intestinal absorption of lead in children and adults: overview of biological and biophysico-chemical aspects. Chem Spec Bioavail 1991; 3: 87-104.
21. Heimann G,. Enteral absorption and bioavailability in children in relation to age. Eur J Clin Pharmacol 1980; 18: 43-50.
22. Edington AM, Fokati N,. Oral drug absorption in pediatric populations. In: Oral Drug Absorption: Prediction and Assessment, 2nd edn. eds, Dressman J, Reppas C,. New York: Informa Healthcare, 2010; 108-126.
23. Johnson TN, Thomson M,. Intestinal metabolism and transport of drugs in children: the effects of age and disease. J Pediatr Gastroenterol Nutr 2008; 47: 3-10.
24. Fakhoury M, Litalien C, Medard Y, Cavé H, Ezzahir N, Peuchmaur M, Jacqz-Aigrain E,. Localization and mRNA expression of CYP3A and P-glycoprotein in human duodenum as a function of age. Drug Metab Dispos 2005; 33: 1603-1607.
25. Kolars JC, Awni WM, Merion RM, Watkins PB,. First-pass metabolism of cyclosporin by gut. Lancet 1991; 338: 1488-1490.
26. Holtbecker N, Fromm MF, Kroemer HK, Ohnhaus EE, Heidemann H,. The nifedipine-rifampin interaction: evidence for induction of gut wall metabolism. Drug Metab Dispos 1996; 24: 1121-1123.
27. Paine MF, Shen DD, Kunze KL, Perkins JD, Marsh CL, McVicar JP, Barr DM, Gillies BS, Thummel KE,. First-pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther 1996; 60: 14-24.
28. Von Richter O, Greiner B, Fromm MF, Fraser R, Omari T, Barclay ML, Dent J, Somogyi AA, Eichelbaum M,. Determination of in vivo absorption, metabolism, and transport of drugs by the human intestinal wall and liver with a novel perfusion technique. Clin Pharmacol Ther 2001; 70: 217-227.
29. Paine MF, Khalighi M, Fisher JM, Shen DD, Kunze KL, Marsh CL, Perkins JD, Thummel KE,. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther 1997; 283: 1552-1562.
30. Johnson TN, Tanner MS, Taylor CJ, Tucker GT,. Enterocytic CYP3A4 in a paediatric population: developmental changes and the effect of coeliac disease and cystic fibrosis. Br J Clin Pharmacol 2001; 51: 451-460.
31. Ginsberg G, Hattis D, Sonawane B, Russ A, Banati P, Kozlak M, Smolenski S, Goble R,. Evaluation of child/adult pharmacokinetic differences from a database derived from the therapeutic drug literature. Toxicol Sci 2002; 66: 185-200.
32. Puig M,. Body composition and growth. In: Nutrition in Pediatrics, 2nd edn. eds, Walker WA, Watkins JB,. Hamilton, ON: BC Decker, 1996; 122-141.
33. Milsap RL, Jusko WJ,. Pharmacokinetics in the infant. Environ Health Perspect 1994; 102: (Suppl. 11): 107-110.
34. Morselli P, Morselli R, Bossi L,. Clinical pharmacokinetics in newborns and infants. In: Handbook of Clinical Pharmacokinetics, Section II, eds, Gibaldi M, Prescott L,. New York: ADIS Health Sciences Press, 1983; 98-141.
35. Brown RD, Campoli-Richards DM,. Antimicrobial therapy in neonates, infants and children. Clin Pharmacokinet 1989; 17: (Suppl. 1): 105-115.
36. Radde IC,. Mechanisms of drug absorption and their development. In: Textbook of Pediatric Clinical Pharmacology, eds, McLeod HL, Radde IC,. Littleton, CO: PSG Publishing, 1985; 17-43.
37. Chignell CF, Vesell ES, Starkwea DK, Berlin CM,. Binding of sulfaphenazole to fetal neonatal and adult plasma albumin. Clin Pharmacol Ther 1971; 12: 897-901.
38. Ehrnebo M, Agurell S, Jalling B, Boréus LO,. Age differences in drug binding by plasma proteins: studies on human foetuses, neonates and adults. Eur J Clin Pharmacol 1971; 3: 189-193.
39. Krasner J, Giacoia GP, Yaffe SJ,. Drug-protein binding inthe newborn infant. Ann N Y Acad Sci 1973; 226: 101-114.
40. Marselli PL,. Clinical pharmacokinetics in neonates. Clin Pharmacokinet 1976; 1: 82-98.
41. Barter ZE, Bayliss MK, Beaune PH, Boobis AR, Carlile DJ, Edwards RJ, Houston JB, Lake BG, Lipscomb JC, Pelkonen OR, Tucker GT, Rostami-Hodjegan A,. Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. Curr Drug Metab 2007; 8: 33-45.
42. Gibbs JP, Murray G, Risler L, Chien JY, Dev R, Slattery JT,. Age-dependent tetrahydrothiophenium ion formation in young children and adults receiving high-dose busulfan. Cancer Res 1997; 57: 5509-5516.
43. Rane A,. Drug disposition and action in infants and children. In: Pediatric Pharmacology Therapeutic Principles in Practice, eds, Yaffe SJ, Aranda JV,. Philadelphia, PA: W B Saunders Co, 1992; 10-21.
44. Weiss CF, Glazko AJ, Weston JK,. Chloramphenicol in the newborn infant. N Engl J Med 1960; 262: 787-794.
45. Boucher FD, Modlin JF, Weller S, Ruff A, Mirochnick M, Pelton S, Wilfert C, McKinney R, Crain MJ, Elkins MM,. Phase I evaluation of zidovudine administered to infants exposed at birth to the human immunodeficiency virus. J Pediatr 1993; 122: 137-144.
46. de Wildt SN, Kearns GL, Hop WC, Murry DJ, Abdel-Rahman SM, van den Anker JN,. Pharmacokinetics and metabolism of oral midazolam in preterm infants. Br J Clin Pharmacol 2002; 53: 390-392.
47. Benedetti MS, Whomsley R, Canning M,. Drug metabolism in the paediatric population and in the elderly. Drug Discov Today 2007; 12: 599-610.
48. Hines RN,. The ontogeny of drug metabolism enzymes and implications for adverse drug events. Pharmacol Ther 2008; 118: 250-267.
49. De Wildt SN,. Profound changes in drug metabolism enzymes and possible effects on drug therapy in neonates and children. Expert Opin Drug Metab Toxicol 2011; 7: 935-948.
50. Blake MJ, Castro L, Leeder JS, Kearns GL,. Ontogeny of drug metabolizing enzymes in the neonate. Semin Fetal Neonatal Med 2005; 10: 123-138.
51. Koukouritaki SB, Manro JR, Marsh SA, Stevens JC, Rettie AE, McCarver DG, Hines RN,. Developmental expression of human hepatic CYP2C9 and CYP2C19. J Pharmacol Exp Ther 2004; 308: 965-974.
52. Hines RN, McCarver DG,. The ontogeny of human drug-metabolizing enzymes: phase I oxidative enzymes. J Pharmacol Exp Ther 2002; 300: 355-360.
53. McCarver DG, Hines RN,. The ontogeny of human drug-metabolizing enzymes: phase II conjugation enzymes and regulatory mechanisms. J Pharmacol Exp Ther 2002; 300: 361-366.
54. Kurokawa K, Itoh T, Kuwahara T, Oshima K, Toh H, Toyoda A, Takam H, Morita H, Sharma VK, Srivastava TP, Taylor TD, Noguchi H, Mori H, Ogura Y, Ehrlich DS, Itoh K, Takagi T, Sakaki Y, Hayashi T, Hattori M,. Comparative metagenomics revealed commonly enriched gene sets in human gut microbiomes. DNA Res 2007; 14: 169-181.
55. Linday L, Dobkin JF, Wang TC, Butler VP Jr, Saha JR, Lindenbaum J,. Digoxin inactivation by the gut flora in infancy and childhood. Pediatrics 1987; 79: 544-548.
56. Committee PF. British National Formulary for Children (BNFC) (Online). London: BMJ Group, Pharmaceutical Press, and RCPCH Publications, 2012. Available at http://www.rcpch.ac.uk/what-we-do/rcpch-publications/british-national-formulary-children-bnfc/british-national-formulary-ch (last accessed 1 October 2013).
57. Andrieux C, Membré JM, Cayuela C, Antoine JM,. Metabolic characteristics of the faecal microflora in humans from three age groups. Scand J Gastroenterol 2002; 37: 792-798.
58. Palmer C, Bik EM, DiGiulio DB, Relman DA, Brown PO,. Development of the human infant intestinal microbiota. PLoS Biol 2007; 5: e177.
59. Matamoros S, Gras-Leguen C, Le Vacon F, Potel G, de La Cochetiere M-F,. Development of intestinal microbiota in infants and its impact on health. Trends Microbiol 2013; 21: 167-173.
60. Huang CT, Rodriguez JT, Woodward WE, Nichols BL,. Comparison of patterns of fecal bile acid and neutral sterol between children and adults. Am J Clin Nutr 1976; 29: 1196-1203.
61. Anderson BJ, Holford NHG,. Understanding dosing: children are small adults, neonates are immature children. Arch Dis Child 2013; 98: 737-744.
62. Patsalos PN,. Clinical pharmacokinetics of levetiracetam. Clin Pharmacokinet 2004; 43: 707-724.
63. Somogyi A, Becker M, Gugler R,. Cimetidine pharmacokinetics and dosage requirements in children. Eur J Pediatr 1985; 144: 72-76.
64. Chae KM, Tharp MD,. Use and safety of antihistamines in children. Dermatol Ther 2000; 13: 374-383.
65. Chen N, Aleksa K, Woodland C, Rieder M, Koren G,. Ontogeny of drug elimination by the human kidney. Pediatr Nephrol 2006; 21: 160-168.
66. Schwartz G,. Does kL/PCr estimate GFR, or does GFR determine k? Pediatr Nephrol 1992; 6: 512-515.
67. Alcorn J, McNamara PJ,. Using ontogeny information to build predictive models for drug elimination. Drug Discov Today 2008; 13: 507-512.
68. Bourgeois FT, Murthy S, Pinto C, Olson KL, Ioannidis JPA, Mandl KD,. Pediatric versus adult drug trials for conditions with high pediatric disease burden. Pediatrics 2012; 130: 285-292.
69. De Cock RFW, Piana C, Krekels EHJ, Danhof M, Allegaert K, Knibbe CAJ,. The role of population PK-PD modelling in paediatric clinical research. Eur J Clin Pharmacol 2011; 67: (Suppl. 1): S5-S16.
70. Donald PR, Maritz JS, Diacon AH,. The pharmacokinetics and pharmacodynamics of rifampicin in adults and children in relation to the dosage recommended for children. Tuberculosis 2011; 91: 196-207.
71. Rodman JH, Relling MV, Stewart CF, Synold TW, McLeod H, Kearns C, Stute N, Crom WR, Evans WE,. Clinical pharmacokinetics and pharmacodynamics of anticancer drugs in children. Semin Oncol 1993; 20: 18-29.
72. Standing JF, Tsolia M, Lutsar I,. Pharmacokinetics and pharmacodynamics of oseltamivir in neonates, infants and children. Infect Disord Drug Targets 2013; 13: 6-14.
73. Zuppa AF, Barrett JS,. Pharmacokinetics and pharmacodynamics in the critically ill child. Pediatr Clin North Am 2008; 55: 735-755.
74. Johnson TN,. The problems in scaling adult drug doses to children. Arch Dis Child 2008; 93: 207-211.
75. FDA. Guidance for industry. Exposure-response relationships-study design, data analysis, and regulatory applications. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). 2003; Available at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072109.pdf (last accessed 11 October 2013).
76. Rodriguez W, Selen A, Avant D, Chaurasia C, Crescenzi T, Gieser G, Di Giacinto J, Huang S-M, Lee P, Mathis L, Murphy D, Murphy S, Roberts R, Sachs HC, Suarez S, Tandon V, Uppoor RS,. Improving pediatric dosing through pediatric initiatives: what we have learned. Pediatrics 2008; 121: 530-539.
77. EMA. Guideline on the role of pharmacokinetics in the development of medicinal products in the paediatric population, Corrigendum. EMEA/CHMP/EWP/147013/2004 2006; Available at http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003066.pdf (last accessed 11 October 2013).
78. Baiardi P, Giaquinto C, Girotto S, Manfredi C, Ceci A,. Innovative study design for paediatric clinical trials. Eur J Clin Pharmacol 2011; 67: 109-115.
79. EMA. Guideline on the investigation of medicinal products in the term and preterm neonate. European Medicines Agency Commitee for medicinalproduicts for human use (CHMP) and paediatric committee (PDCO). 2010. Available at http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003754.pdf (last accessed 11 October 2013).
80. Al-Obaidy SS, Li Wan Po A, McKiernan PJ, Glasgow JFT, Millership J,. Assay of paracetamol and its metabolites in urine, plasma and saliva of children with chronic liver disease. J Pharm Biomed Anal 1995; 13: 1033-1039.
81. Kole PL, Millership J, McElnay JC,. Determination of diclofenac from paediatric urine samples by stir bar sorptive extraction (SBSE) HPLC UV technique. Talanta 2011; 85: 1948-1958.
82. Patel P, Mulla H, Tanna S, Pandya H,. Facilitating pharmacokinetic studies in children: a new use of dried blood spots. Arch Dis Child 2010; 95: 484-487.
83. Cohen-Wolkowiez M, Benjamin DK, Ross A, James LP, Sullivan JE, Walsh MC, Zadell A, Newman N, White NR, Kashuba ADM, Ouellet D,. Population pharmacokinetics of piperacillin using scavenged samples from preterm infants. Ther Drug Monit 2012; 34: 312-319.
84. Cohen-Wolkowiez M, Ouellet D, Smith PB, James LP, Ross A, Sullivan JE, Walsh MC, Zadell A, Newman N, White NR, Kashuba ADM, Benjamin DK,. Population pharmacokinetics of metronidazole evaluated using scavenged samples from preterm infants. Antimicrob Agents Chemother 2012; 56: 1828-1837.
85. Grasela TH Jr, Donn SM,. Neonatal population pharmacokinetics of phenobarbital derived from routine clinical data. Dev Pharmacol Ther 1985; 8: 374-383.
86. FDA. Guidance for industry. Population pharmacokinetics. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). 1999; Available at http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/WomensHealthResearch/UCM133184.pdf (last accessed 11 October 2013).
87. EMA. Guideline on the role of pharmacokinetics in the development of medicinal products in the paediatric population Committee for Medicinal Products for Human Use (CHMP). 2007; Available at http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003066.pdf (last accessed 11 October 2013).
88. Edginton AN, Theil F-P, Schmitt W, Willmann S,. Whole body physiologically-based pharmacokinetic models: their use in clinical drug development. Expert Opin Drug Metab Toxicol 2008; 4: 1143-1152.
89. Tod M, Jullien V, Pons G,. Facilitation of drug evaluation in children by population methods and modelling. Clin Pharmacokinet 2008; 47: 231-243.
90. Johnson TN, Rostami-Hodjegan A, Tucker GT,. Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin Pharmacokinet 2006; 45: 931-956.
91. Krekels EHJ, Van Hasselt JGC, Tibboel D, Danhof M, Knibbe CAJ,. Systematic evaluation of the descriptive and predictive performance of paediatric morphine population models. Pharm Res 2011; 28: 797-811.
92. Läer S, Khalil F,. Physiologically based pharmacokinetic modeling: methodology, applications, and limitations with a focus on its role in pediatric drug development. J Biomed Biotechnol 2011; 2011: 907461.
93. Cella M, Zhao W, Jacqz-Aigrain E, Burger D, Danhof M, Pasqua OD,. Paediatric drug development: are population models predictive of pharmacokinetics across paediatric populations? Br J Clin Pharmacol 2011; 72: 454-464.
94. Barrett JS, Della Casa Alberighi O, Laer S, Meibohm B,. Physiologically based pharmacokinetic (PBPK) modeling in children. Clin Pharmacol Ther 2012; 92: 40-49.
95. Strougo A, Eissing T, Yassen A, Willmann S, Danhof M, Freijer J,. First dose in children: physiological insights into pharmacokinetic scaling approaches and their implications in paediatric drug development. J Pharmacokinet Pharmacodyn 2012; 39: 195-203.
96. Rowland M, Peck C, Tucker G,. Physiologically-based pharmacokinetics in drug development and regulatory science. Annu Rev Pharmacol Toxicol 2011; 51: 45-73.
97. Jadhav PR, Zhang J, Gobburu JVS,. Leveraging prior quantitative knowledge in guiding pediatric drug development: a case study. Pharm Stat 2009; 8: 216-224.
98. Reigner B,. Clinical pharmacology considerations in paediatric development. 'Paediatric Clinical Trials meeting' SMi, London, March 20-21. 2013.
99. Viergever RF, Rademaker CMA, Ghersi D,. Pharmacokinetic research in children: an analysis of registered records of clinical trials. BMJ Open 2011; 1: e000221.